- NZ$7.30bn
- NZ$8.87bn
- AU$13.19bn
- 94
- 55
- 78
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.37 | ||
| PEG Ratio (f) | 2.95 | ||
| EPS Growth (f) | 8.2% | ||
| Dividend Yield (f) | 3.3% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.69 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 21.12 | ||
| Price to Sales | 0.53 | ||
| EV to EBITDA | 14.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.16% | ||
| Return on Equity | 10.15% | ||
| Operating Margin | 3.55% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 8,765.54 | 9,202.89 | 10,734.12 | 12,237.4 | 13,189.05 | 12,138.97 | 12,867.28 | 13.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +7.09 | +12.87 | +10.18 | +8.95 | +7.57 | -6.11 | +13.72 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EBOS Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care, and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services, and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. It sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.
Directors
- Elizabeth Coutts NEC
- John Matthew Cullity CEO
- Leonard Hansen CFO
- Brett Barons CEX
- Julie Dillon CEX
- Andrea Bell CIO
- Janelle Cain GCN
- Jacinta McCarthy GMG
- Simon Bunde GMG
- David Lewis GMG
- Tracey Batten NID (55)
- Nicholas Dowling NID
- Stuart McGregor NID
- Stuart McLauchlan NID
- Sarah Ottrey NID
- Peter Williams NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 11th, 1922
- Public Since
- June 16th, 1986
- No. of Shareholders
- 12,298
- No. of Employees
- 5,200
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New Zealand Stock Exchange- Shares in Issue
- 194,685,000
- Address
- Level 7, 737 Bourke Street,, Docklands, CHRISTCHURCH, 3008
- Web
- https://www.ebosgroup.com/
- Phone
- +64 33380999
- Auditors
- Deloitte
Upcoming Events for EBO
Similar to EBO
AFT Pharmaceuticals
New Zealand Stock Exchange
BLIS Technologies
New Zealand Stock Exchange
Rua Bioscience
New Zealand Stock Exchange
FAQ
What is the EBOS share price?
As of Today at 19:21 UTC, shares in EBOS are trading at NZ$37.50. This share price information is delayed by 15 minutes.
How has the EBOS share price performed this year?
Shares in EBOS last closed at NZ$37.50 and the price had moved by +5.34% over the past 365 days. In terms of relative price strength the EBOS share price has outperformed the ASX All Ordinaries Index by +4.22% over the past year.
What are the analyst and broker recommendations for EBOS?
The overall consensus recommendation for EBOS is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the EBOS dividend yield?
The EBOS dividend yield is 3.14% based on the trailing twelve month period.
Does EBOS pay a dividend?
Last year, EBOS paid a total dividend of AU$1.08, and it currently has a trailing dividend yield of 3.14%. We do not have any data on when EBOS is to next pay dividends.
When does EBOS next pay dividends?
We do not have data on when EBOS is to next pay dividends. The historic dividend yield on EBOS shares is currently 3.14%.
How do I buy EBOS shares?
To buy shares in EBOS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of EBOS?
As of the previous close price of NZ$37.50, shares in EBOS had a market capitalisation of NZ$7.30bn.
Where are EBOS shares listed?
Here are the trading details for EBOS:
- Country of listing: New Zealand
- Exchange: NZC
- Ticker Symbol: EBO
What kind of share is EBOS?
Based on an overall assessment of its quality, value and momentum EBOS is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a EBOS share price forecast for 2025?
The analyst consensus target price for shares in EBOS is NZ$41.79. That is 11.44% above the last closing price of NZ$37.50.
Analysts covering EBOS currently have a consensus Earnings Per Share (EPS) forecast of AU$1.39 for the next financial year.
Find out moreWhat is the trend in the EBOS share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like EBOS. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +7.66%.
As of the last closing price of NZ$37.50, shares in EBOS were trading +2.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the EBOS PE Ratio?
The EBOS PE ratio based on its reported earnings over the past 12 months is 22.37. The shares last closed at NZ$37.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of EBOS?
EBOS' management team is headed by:
- Elizabeth Coutts - NEC
- John Matthew Cullity - CEO
- Leonard Hansen - CFO
- Brett Barons - CEX
- Julie Dillon - CEX
- Andrea Bell - CIO
- Janelle Cain - GCN
- Jacinta McCarthy - GMG
- Simon Bunde - GMG
- David Lewis - GMG
- Tracey Batten - NID
- Nicholas Dowling - NID
- Stuart McGregor - NID
- Stuart McLauchlan - NID
- Sarah Ottrey - NID
- Peter Williams - NID